-
Preclinical Data Shows That ELX-02 Increase CFTR Levels
At the 2019 European Cystic Fibrosis Society (ECFS) Basic Science Conference in March, Eloxx Pharmaceuticals presented new positive preclinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), demonstrating that the therapy increases the levels of CFTR protein and its correct placement at the cell’s surface in patient-derived organoids. Click here to learn more.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.